Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-SCAPE: Grazoprevir +/- Elbasvir +/- Ribavirin in HCV GT 2, 4, 5, 6
NCT01932762Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of grazoprevir and elbasvir in hepatitis C (HCV) (4 arms), sponsored by Merck & Co. Primary endpoints: Sustained Virologic Response 12 Weeks After End of Therapy at 24 weeks and Percentage of Participants With Adverse Events at 14 weeks. Started Oct 2013; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01932762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01932762.